Resumo:
En
|
Texto:
En
|
PDF:
En
Abstract Objective: We conducted a meta-analysis of randomized clinical trials evaluating the clinical effects of ferric carboxymaltose therapy compared to other intravenous iron in improving hemoglobin and serum ferritin in pregnant women. We also assessed the safety of ferric carboxymaltose vs. other intravenous iron. Data source: EMBASE, PubMed, and Web of Science were searched for trials related to ferric carboxymaltose in pregnant women, published between 2005 and 2021. We also reviewed articles from google scholar. The keywords "ferric carboxymaltose," "FCM," "intravenous," "randomized," "pregnancy," "quality of life," and "neonatal outcomes" were used to search the literature. The search was limited to pregnant women. Selection of studies: Studies related to ferric carboxymaltose in pregnancy were scanned. Observational studies, review articles, and case reports were excluded. Randomized studies in pregnant women involving ferric carboxymaltose and other intravenous iron formulations were shortlisted. Of 256 studies, nine randomized control trials were selected. Data collection: Two reviewers independently extracted data from nine selected trials Data synthesis: The final effect size for increase in hemoglobin after treatment was significant for ferric carboxymaltose vs. iron sucrose/iron polymaltose (standard mean difference 0.89g/dl [95% confidence interval 0.27,1.51]). The final effect size for the increase in ferritin after treatment was more for ferric carboxymaltose vs. iron sucrose/iron polymaltose (standard mean difference 22.53µg/L [-7.26, 52.33]). No serious adverse events were reported with ferric carboxymaltose or other intravenous iron. Conclusion: Ferric carboxymaltose demonstrated better efficacy than other intravenous iron in increasing hemoglobin and ferritin levels in treating iron deficiency anemia in pregnant women. Objective metaanalysis meta analysis vs source EMBASE PubMed 200 2021 scholar carboxymaltose, FCM, FCM "FCM, intravenous, "intravenous, randomized, "randomized, pregnancy, "pregnancy, quality life, life neonatal outcomes literature scanned excluded shortlisted 25 collection synthesis sucroseiron sucrose standard 089gdl gdl 0 89g dl g 95% 95 [95 0.27,1.51. 027151 0.27,1.51 . 27 1 51 0.27,1.51]) 2253µgL µgL 22 53µg L µg 7.26, 726 7 26 [-7.26 52.33. 5233 52.33 52 33 52.33]) Conclusion 20 202 "FCM "intravenous "randomized "pregnancy 2 9 [9 02715 0.27,1.5 5 0.27,1.51] 7.26 72 [-7.2 523 52.3 3 52.33] [ 0271 0.27,1. 7.2 [-7. 52. 027 0.27,1 7. [-7 02 0.27, [- 0.27 0.2 0.